2-(2-amino-4-benzyloxy-5-methoxyphenyl)-N-benzyl-2-(4-cyanophenylamino)acetamide | 227021-84-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2-amino-4-benzyloxy-5-methoxyphenyl)-N-benzyl-2-(4-cyanophenylamino)acetamide
• 英文别名: 2-(2-amino-5-methoxy-4-phenylmethoxyphenyl)-N-benzyl-2-(4-cyanoanilino)acetamide
• CAS: 227021-84-3
• 化学式: C₃₀H₂₈N₄O₃
• 分子量: 492.577
• InChiKey: JLGCLUWZAYARGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(2-amino-4-benzyloxy-5-methoxyphenyl)-N-benzyl-2-(4-cyanophenylamino)acetamide 在 TEA 、 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 2-(2-Benzenesulfonylamino-4-benzyloxy-5-methoxy-phenyl)-N-benzyl-2-[4-(N-hydroxycarbamimidoyl)-phenylamino]-acetamide
  参考文献：
  名称：

  Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors

  摘要：

  Proof of concept experiments have shown that tissue factor/factor Vila inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue factor/factor Vila inhibitors with low nanomolar affinity and good selectivity against other serine proteases of the coagulation cascade were designed, using the guidance of X-ray structural analysis and molecular modelling. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.092
• 作为产物：
  描述：

  4-(苄氧基)-5-甲氧基-2-硝基苯甲醛 在 palladium on activated charcoal 三氟化硼乙醚 、 氢气 作用下， 以 various solvent(s) 为溶剂， 反应 1.0h， 生成 2-(2-amino-4-benzyloxy-5-methoxyphenyl)-N-benzyl-2-(4-cyanophenylamino)acetamide
  参考文献：
  名称：

  Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors

  摘要：

  Proof of concept experiments have shown that tissue factor/factor Vila inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue factor/factor Vila inhibitors with low nanomolar affinity and good selectivity against other serine proteases of the coagulation cascade were designed, using the guidance of X-ray structural analysis and molecular modelling. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.092

文献信息

• N-(4-carb-amimidophenyl)glycineamide derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06140353A1

  公开（公告）日：2000-10-31

  N-(4-carbamimidophenylamino) phenylglycineamide derivative compounds having the formula: ##STR1## in which E, g.sup.1, g.sup.2, Q, R and X.sup.1 to X.sup.4 are each as defined in the description, and hydrates or solvates and physiologically acceptable salts thereof can be used as inhibitors of the formation of the coagulation factors Xa, IXa and thrombin induced by the factor VIIa and by the tissue factor. These compounds can be used as medicaments for the treatment and/or prevention of thromboses, apoplexy, cardiac infarction, inflammation and arteriosclerosis or as antitumor agents.

  具有以下结构式的N-(4-氨基甲酰基苯基氨基)苯基甘氨酰胺衍生物化合物：在该结构式中，E、g.sup.1、g.sup.2、Q、R和X.sup.1至X.sup.4的定义如描述中所述，并且其水合物或溶剂化合物以及其生理学上可接受的盐可用作抑制由因子VIIa和组织因子诱导的凝血因子Xa、IXa和凝血酶的形成的药物。这些化合物可用作治疗和/或预防血栓、中风、心肌梗死、炎症和动脉粥样硬化的药物，或者用作抗肿瘤剂。
• N-(4-carbamimido-phenyl)-glycinamidderivate
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0921116B1

  公开（公告）日：2003-06-18
• US6140353A
  申请人：——

  公开号：US6140353A

  公开（公告）日：2000-10-31
• Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
  作者：Katrin Groebke Zbinden、David W. Banner、Jean Ackermann、Allan D’Arcy、Daniel Kirchhofer、Yu-Hua Ji、Thomas B. Tschopp、Sabine Wallbaum、Lutz Weber

  DOI：10.1016/j.bmcl.2004.10.092

  日期：2005.2

  Proof of concept experiments have shown that tissue factor/factor Vila inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue factor/factor Vila inhibitors with low nanomolar affinity and good selectivity against other serine proteases of the coagulation cascade were designed, using the guidance of X-ray structural analysis and molecular modelling. (C) 2004 Elsevier Ltd. All rights reserved.